American hematologist-oncologist and health researcher, director of the FDA's Center for Biologics Evaluation and Research since May 2025.
Moderna’s mFlusiva has secured an advisory committee vote in favor of approval for adults 50 and older. The decision follows earlier FDA scrutiny and a high-profile dispute over study design, with the committee citing robust efficacy and a solid safety profile.
Moderna has won FDA approval for its mRNA flu vaccine mFlusiva for adults 50–64 and accelerated approval for those 65 and older. The decision follows a contentious review earlier this year, a unanimous advisory panel recommendation in June and political disputes inside US health agencies over mRNA vaccines. Retail availability is expected in coming weeks.